We are live on ! Find out more
GCP

GSA Capital Partners Portfolio holdings

AUM $1.59B
1-Year Est. Return 39.81%
This Fund
S&P 500
This Quarter Est. Return
-2.76%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$754M
AUM Growth
+$87.8M
Cap. Flow
+$160M
Cap. Flow %
21.21%
Top 10 Hldgs %
3.31%
Holding
2,028
New
691
Increased
437
Reduced
328
Closed
568

Sector Composition

Rank Sector Weight
1 Healthcare 16.63%
2 Consumer Discretionary 15.71%
3 Technology 14.34%
4 Industrials 12%
5 Financials 11.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GTX icon
1351
Garrett Motion
GTX
$5.57B
$109K 0.01%
19,328
-12,441
-39% -$85.4K
OCFT
1352
DELISTED
OneConnect Financial Technology
OCFT
$108K 0.01%
15,020
+1,613
+12% +$21.2K
IVC
1353
DELISTED
Invacare Corporation
IVC
$107K 0.01%
+137,014
New +$144K
PASG icon
1354
Passage Bio
PASG
$14.1M
$106K 0.01%
4,260
-225
-5% -$8.87K
HARP
1355
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$106K 0.01%
+10,914
New +$204K
PLTK icon
1356
Playtika
PLTK
$1.12B
$105K 0.01%
11,135
-29,470
-73% -$340K
TME icon
1357
Tencent Music
TME
$15.6B
$105K 0.01%
25,782
-57,067
-69% -$260K
SCU
1358
DELISTED
Sculptor Capital Management, Inc. Class A Common Stock
SCU
$104K 0.01%
11,788
-26,294
-69% -$243K
DSKE
1359
DELISTED
Daseke, Inc. Common Stock
DSKE
$103K 0.01%
+19,070
New +$123K
GMBL
1360
DELISTED
Esports Entertainment Group Inc. Common Stock
GMBL
$103K 0.01%
+21
New +$329K
PTGX icon
1361
Protagonist Therapeutics
PTGX
$9.44B
$102K 0.01%
+12,145
New +$115K
OMIC
1362
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$102K 0.01%
+1,356
New +$142K
DNMR
1363
DELISTED
Danimer Scientific, Inc.
DNMR
$101K 0.01%
853
+584
+217% +$104K
EOLS icon
1364
Evolus
EOLS
$501M
$99K 0.01%
+12,330
New +$131K
KODK icon
1365
Kodak
KODK
$983M
$99K 0.01%
+21,663
New +$118K
OHPA
1366
DELISTED
Orion Acquisition Corp. Class A common stock
OHPA
$99K 0.01%
+10,100
New +$99.3K
AMYT
1367
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$98K 0.01%
14,094
+1,156
+9% +$8.63K
ZYNE
1368
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$96K 0.01%
131,036
-1,369
-1% -$1.55K
IMUX icon
1369
Immunic
IMUX
$195M
$94K 0.01%
+2,972
New +$124K
INSE icon
1370
Inspired Entertainment
INSE
$175M
$94K 0.01%
10,672
-26,209
-71% -$270K
LADR
1371
Ladder Capital
LADR
$1.24B
$94K 0.01%
+10,473
New +$116K
API
1372
Agora
API
$377M
$93K 0.01%
25,709
-7,001
-21% -$33.1K
NAUT icon
1373
Nautilus Biotechnolgy
NAUT
$115M
$91K 0.01%
+43,030
New +$108K
RSI icon
1374
Rush Street Interactive
RSI
$2.88B
$91K 0.01%
+24,648
New +$130K
ICVX
1375
DELISTED
Icosavax, Inc. Common Stock
ICVX
$91K 0.01%
+28,866
New +$181K

Similar funds

GSA Capital Partners's Q3 2022 Portfolio in Review

As of Q3 2022, GSA Capital Partners held 2,028 positions worth $754M, up 13% from $666M the previous quarter. Its ten largest holdings account for 3.3% of the portfolio.

GSA Capital Partners deployed $160M of net new capital in Q3 2022, opening 691 new positions and adding to 437 existing holdings. Its largest new stake was Dave & Buster's: 75,954 shares worth $2.36M.

By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 18% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Genpact, an estimated $3.61M trimmed.

  • GSA Capital Partners's largest Q3 2022 buy was Dave & Buster's: 75,954 shares worth $2.36M.
  • GSA Capital Partners added most to Grocery Outlet in Q3 2022, an estimated $2.54M increase.
  • GSA Capital Partners's biggest Q3 2022 reduction was Genpact, cutting an estimated $3.61M.
  • GSA Capital Partners fully exited Relay Therapeutics in Q3 2022, selling an estimated $2.99M.
  • GSA Capital Partners's ten largest holdings make up 3.3% of its $754M portfolio in Q3 2022.
  • GSA Capital Partners opened 691 new positions and closed 568 in Q3 2022.
  • GSA Capital Partners's portfolio value rose 13% quarter-over-quarter to $754M.

Based on GSA Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.